Drugs / AZD5055
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05644600 | May → Jul 2023 | — | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT05630677 | Nov 2022 → Feb 2023 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05134727 | Nov 2021 → Mar 2023 | idiopathic pulmonary fibrosis | AstraZeneca | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05955183 Comparator | Jul → Dec 2023 | — | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD5055 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05955183 ↗ |
| Route | Oral | “Oral AZD5055” NCT05134727 ↗ |